Nuclear medicine firm Digirad has beaten back a challenge by a disgruntled shareholder that sought to replace the company's board of directors in a proxy contest.
The company reported that at its May 3 annual meeting, Digirad shareholders voted to elect each of the company's five nominees to the board of directors. The Digirad slate consisted of Jeffrey E. Eberwein, John M. Climaco, Charles M. Gillman, James B. Hawkins, and John W. Sayward.
More than 15 million votes were cast, representing about 78% of outstanding shares, according to Digirad. A solid majority was cast for each of the five Digirad nominees, and shareholders also approved all three proposals on the ballot, the company noted.
The Digirad slate had been challenged by Red Oak Partners, a Digirad shareholder that nominated an alternative group of candidates for the board. In an April letter to shareholders, Red Oak charged that Digirad's current board lacks experience in the medical imaging industry and in leading corporate turnaround efforts.
